%	O
%	O
TITLE	O

Cost	B-Study_Type
-	I-Study_Type
effectiveness	I-Study_Type
of	O
introducing	O
the	O
10	O
-	O
valent	O
pneumococcal	O
conjugate	O
vaccine	O
into	O
the	O
universal	O
immunisation	O
of	O
infants	O
in	O
Brazil	B-Study_Location
.	O

%	O
%	O
ABSTRACT	O

Cost	B-Study_Type
-	I-Study_Type
effectiveness	I-Study_Type
studies	I-Study_Type
have	O
been	O
increasingly	O
part	O
of	O
decision	O
processes	O
for	O
incorporating	O
new	O
vaccines	O
into	O
the	O
Brazilian	O
National	O
Immunisation	O
Program	O
.	O

This	B-Study_Purpose
study	I-Study_Purpose
aimed	I-Study_Purpose
to	I-Study_Purpose
evaluate	I-Study_Purpose
the	I-Study_Purpose
cost	I-Study_Purpose
-	I-Study_Purpose
effectiveness	I-Study_Purpose
of	I-Study_Purpose
10	I-Study_Purpose
-	I-Study_Purpose
valent	I-Study_Purpose
pneumococcal	I-Study_Purpose
conjugate	I-Study_Purpose
vaccine	I-Study_Purpose
(	I-Study_Purpose
PCV10	I-Study_Purpose
)	I-Study_Purpose
in	I-Study_Purpose
the	I-Study_Purpose
universal	I-Study_Purpose
childhood	I-Study_Purpose
immunisation	I-Study_Purpose
programme	I-Study_Purpose
in	I-Study_Purpose
Brazil	B-Study_Location
.	O
A	O
decision	O
-	O
tree	O
analytical	O
model	O
based	O
on	O
the	O
ProVac	O
Initiative	O
pneumococcus	O
model	O
was	O
used	O
,	O
following	O
25	O
successive	O
cohorts	O
from	O
birth	O
until	O
5	B-Maximum_Age_in_Study_Cohort
years	O
of	O
age	O
.	O

Two	O
strategies	O
were	O
compared	O
:	O
(	O
1	O
)	O
status	O
quo	O
and	O
(	O
2	O
)	O
universal	O
childhood	O
immunisation	O
programme	O
with	O
PCV10	O
.	O

Epidemiological	O
and	O
cost	O
estimates	O
for	O
pneumococcal	O
disease	O
were	O
based	O
on	O
National	O
Health	O
Information	O
Systems	O
and	O
literature	O
.	O

A	O
'	O
top	O
-	O
down	O
'	O
costing	O
approach	O
was	O
employed	O
.	O

Costs	O
are	O
reported	O
in	O
2004	B-Study_Time
Brazilian	O
reals	O
.	O

Costs	O
and	O
benefits	O
were	O
discounted	O
at	O
3	O
%	O
.	O
25	O
years	O
after	O
implementing	O
the	O
PCV10	O
immunisation	O
programme	O
,	O
10â€ˆ226	O
deaths	O
,	O
360â€ˆ657	O
disability	O
-	O
adjusted	O
life	O
years	O
(	O
DALYs	O
)	O
,	O
433â€ˆ808	O
hospitalisations	O
and	O
5â€ˆ117â€ˆ109	O
outpatient	O
visits	O
would	O
be	O
avoided	O
.	O

The	O
cost	O
of	O
the	O
immunisation	O
programme	O
would	O
be	O
R$10â€ˆ674â€ˆ478â€ˆ765	O
,	O
and	O
the	O
expected	O
savings	O
on	O
direct	O
medical	O
costs	O
and	O
family	O
costs	O
would	O
be	O
R$1â€ˆ036â€ˆ958â€ˆ639	O
and	O
R$209â€ˆ919â€ˆ404	O
,	O
respectively	O
.	O

This	O
resulted	O
in	O
an	O
incremental	O
cost	O
-	O
effectiveness	O
ratio	O
of	O
R$778â€ˆ145	O
/	O
death	O
avoided	O
and	O
R$22â€ˆ066	O
/	O
DALY	O
avoided	O
from	O
the	O
society	O
perspective	O
.	O

The	O
PCV10	O
universal	O
infant	O
immunisation	O
programme	O
is	O
a	O
cost	O
-	O
effective	O
intervention	O
(	O
1	O
-	O
3	O
GDP	O
per	O
capita	O
/	O
DALY	O
avoided	O
)	O
.	O

Owing	O
to	O
the	O
uncertain	O
burden	O
of	O
disease	O
data	O
,	O
as	O
well	O
as	O
unclear	O
long	O
-	O
term	O
vaccine	O
effects	O
,	O
surveillance	O
systems	O
to	O
monitor	O
the	O
long	O
-	O
term	O
effects	O
of	O
this	O
programme	O
will	O
be	O
essential	O
.	O

%	O
%	O
METHODS	O

Model	O

A	O
decision	O
-	O
tree	O
analytical	O
model	O
,	O
developed	O
by	O
the	O
ProVac	O
Initiative	O
of	O
the	O
Pan	O
American	O
Health	O
Organization	O
and	O
its	O
partners	O
,	O
was	O
used	O
to	O
estimate	O
the	O
cost	O
-	O
effectiveness	O
of	O
a	O
universal	O
childhood	O
immunisation	O
programme	O
with	O
PCV10	O
in	O
Brazil	O
.	O
6	O
An	O
early	O
version	O
of	O
the	O
model	O
was	O
used	O
.	O

This	O
model	O
has	O
since	O
been	O
superseded	O
by	O
an	O
integrated	O
three	O
-	O
way	O
model	O
(	O
TriVac	O
)	O
developed	O
by	O
ProVac	O
Initiative	O
,	O
which	O
is	O
similar	O
in	O
structure	O
but	O
was	O
not	O
available	O
at	O
the	O
time	O
of	O
the	O
analysis	O
.	O

An	O
in	O
-	O
depth	O
description	O
of	O
the	O
model	O
can	O
be	O
found	O
on	O
the	O
Pan	O
American	O
Health	O
Organization	O
website	O
.	O
7	O

With	O
the	O
ProVac	O
model	O
,	O
25	O
successive	O
cohorts	O
were	O
followed	O
from	O
birth	O
until	O
5	O
years	O
of	O
age	O
.	O

The	O
model	O
captured	O
the	O
effects	O
of	O
vaccination	O
on	O
inva	O
-	O
sive	O
disease	O
(	O
meningitis	O
and	O
sepsis	O
together	O
)	O
,	O
pneumonia	O
and	O
acute	O
otitis	O
media	O
(	O
AOM	O
)	O
.	O

Vacci	O
-	O
nation’s	O
effects	O
were	O
captured	O
by	O
the	O
model	O
as	O

210	O
J	O
Epidemiol	O
Community	O
Health	O
2012	O
;	O
66	O
:	O
210e217	O
.	O

doi	O
:	O
10	O
.	O
1136	O
/	O
jech	O
.	O
2010	O
.	O
111880	O

health	O
burden	O
(	O
cases	O
,	O
deaths	O
,	O
life	O
years	O
,	O
disability	O
-	O
adjusted	O
life	O
years	O
(	O
DALYs	O
)	O
)	O
and	O
economic	O
burden	O
(	O
health	O
systems	O
costs	O
,	O
family	O
costs	O
)	O
.	O

The	O
stream	O
of	O
events	O
in	O
the	O
decision	O
tree	O
is	O
shown	O
in	O
ﬁgure	O
1	O
.	O

The	O
model	O
assessed	O
the	O
cost	O
-	O
effectiveness	O
of	O
a	O
child	O
-	O
hood	O
immunisation	O
programme	O
by	O
comparing	O
two	O
strategies	O
:	O

(	O
1	O
)	O
the	O
current	O
national	O
strategy	O
of	O
vaccinating	O
only	O
high	O
-	O
risk	O
children	O
;	O
and	O
(	O
2	O
)	O
introduction	O
of	O
a	O
universal	O
immunisation	O
programme	O
with	O
PCV10	O
for	O
children	O
in	O
their	O
ﬁrst	O
year	O
of	O
life	O
.	O

According	O
to	O
ﬁgure	O
1	O
,	O
each	O
strategy	O
presents	O
four	O
possibilities	O
:	O
every	O
child	O
may	O
have	O
no	O
PD	O
or	O
invasive	O
pneumococcal	O
disease	O
(	O
IPD	O
)	O
,	O
or	O
pneumonia	O
or	O
AOM	O
.	O

Only	O
vaccine	O
-	O
serotype	O
PD	O
may	O
be	O
averted	O
by	O
vaccination	O
and	O
the	O
model	O
estimated	O
only	O
the	O
burden	O
of	O
disease	O
caused	O
by	O
serotypes	O
included	O
in	O
the	O
PCV10	O
.	O

With	O
PCV10	O
,	O
additional	O
vaccination	O
costs	O
were	O
incurred	O
,	O
and	O
costs	O
were	O
averted	O
when	O
disease	O
was	O
avoided	O
.	O

Health	O
beneﬁts	O
were	O
deaths	O
and	O
non	O
-	O
fatal	O
disease	O
cases	O
averted	O
by	O
immunisation	O
.	O

Costs	O
and	O
health	O
beneﬁts	O
were	O
summarised	O
in	O
incremental	O
cost	O
-	O
effectiveness	O
ratios	O
.	O

The	O
model	O
used	O
did	O
not	O
capture	O
the	O
beneﬁts	O
of	O
the	O
herd	O
effect	O
(	O
ie	O
,	O
protection	O
of	O
the	O
unvaccinated	O
population	O
)	O
or	O
on	O
pneumo	O
-	O
coccal	O
antibiotic	O
-	O
resistance	O
,	O
or	O
the	O
risk	O
of	O
serotype	O
replacement	O

after	O
implementing	O
the	O
universal	O
vaccination	O
.	O

The	O
analysis	O
was	O
conducted	O
from	O
both	O
the	O
societal	O
perspec	O
-	O
tive	O
(	O
including	O
direct	O
and	O
indirect	O
costs	O
)	O
and	O
the	O
healthcare	O
system	O
perspective	O
.	O

All	O
costs	O
were	O
reported	O
in	O
Brazilian	O
reals	O
(	O
2004	O
prices	O
,	O
US$1	O
R$2	O
.	O
65	O
)	O
,	O
and	O
the	O
time	O
frame	O
of	O
the	O
analysis	O
was	O
25	O
years	O
.	O

In	O
accordance	O
with	O
Brazilian	O
and	O
international	O
recommendations	O
,	O
both	O
health	O
and	O
monetary	O
effects	O
were	O
discounted	O
at	O
a	O
rate	O
of	O
3	O
%	O
per	O
year	O
.	O
8	O
9	O
Comprehensive	O
univariate	O
sensitivity	O
analyses	O
were	O
performed	O
to	O
evaluate	O
the	O
effects	O
of	O
uncertainty	O
in	O
key	O
parameters	O
(	O
disease	O
incidence	O
,	O
serotype	O
coverage	O
by	O
vaccine	O
,	O
case	O
death	O
rate	O
,	O
vaccine	O
efﬁcacy	O
,	O
hospital	O
-	O
isation	O
costs	O
,	O
discount	O
rate	O
,	O
number	O
of	O
vaccine	O
doses	O
and	O
price	O
per	O
vaccine	O
dose	O
)	O
of	O
the	O
model	O
.	O

A	O
multivariate	O
sensitivity	O
anal	O
-	O
ysis	O
as	O
best	O
-	O
and	O
worst	O
-	O
case	O
scenarios	O
was	O
performed	O
simulta	O
-	O
neously	O
varying	O
parameters	O
identiﬁed	O
as	O
important	O
in	O
the	O
univariate	O
analysis	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
the	O
Hospital	O
das	O
Clínicas	O
da	O
Faculdade	O
de	O
Medicina	O
da	O
Universidade	O
de	O
São	O
Paulo	O
,	O
Brazil	O
.	O

Epidemiological	O
data	O

Table	O
1	O
presents	O
the	O
epidemiological	O
data	O
of	O
PD	O
in	O
children	O

<	O
5	O
years	O
of	O
age	O
.	O

It	O
was	O
assumed	O
that	O
IPD	B-Pneumococcal_Disease_Type
,	O
including	O
pneumococcal	O
meningitis	O
and	O
pneumococcal	O
sepsis	O
,	O
is	O
always	O
treated	O
in	O

Death	O

No	O
disease	O

hospital	O
.	O

The	O
numbers	O
of	O
hospitalisations	O
due	O
to	O
pneumococcal	O
meningitis	B-Pneumococcal_Disease_Type
and	O
pneumococcal	O
sepsis	B-Pneumococcal_Disease_Type
at	O
the	O
public	O
healthcare	O
system	O
(	O
Sistema	O
Único	O
de	O
Saúde	O
,	O
SUS	O
)	O
in	O
2004	B-Study_Time
,	O
the	O
most	O
recent	O
year	O
for	O
which	O
complete	O
data	O
were	O
available	O
at	O
the	O
time	O
of	O
data	O
collection	O
,	O
were	O
retrieved	O
from	O
the	O
Hospitalisation	O
Information	O
System	O
(	O
Sistema	O
de	O
Informação	O
Hospitalar	O
,	O
SIH	O
/	O
SUS	O
)	O
.	O
10	O
Data	O
from	O
a	O
2003	O
national	O
household	O
survey	O
,	O
which	O
indicated	O
the	O
private	O
healthcare	O
system	O
as	O
responsible	O
for	O
23	O
%	O
of	O
overall	O

hospitalisations	O
of	O
children	O
<	O
5	O
,	O
were	O
used	O
to	O
adjust	O
the	O
total	O
number	O
of	O
hospitalisations	O
.	O
11	O
The	O
total	O
number	O
of	O
hospital	O
-	O
isations	O
was	O
divided	O
by	O
the	O
<	O
5	O
population	O
to	O
calculate	O
IPD	O
incidence	O
rate	O
in	O
children	O
<	O
5	O
(	O
13	O
.	O
59	O
/	O
100	O
000	O
)	O
.	O

IPD	B-Pneumococcal_Disease_Type
may	O
lead	O
to	O
many	O
types	O
of	O
sequelae	O
,	O
but	O
analysis	O
was	O
restricted	O
to	O
deafness	O

and	O
neurological	O
sequelae	O
after	O
meningitis	O
.	O

The	O
risk	O
of	O
sequelae	O
after	O
IPD	B-Pneumococcal_Disease_Type
was	O
based	O
on	O
literature	O
.	O
12e15	O
It	O
was	O
assumed	O
that	O
8	O
.	O
49	O
%	O
of	O
the	O
children	O
evolved	O
to	O
deafness	O
and	O
11	O
.	O
32	O
%	O
with	O
neurological	O
sequelae	O
.	O

Data	O
from	O
the	O
SIH	O
/	O
SUS	O
and	O
from	O
the	O
Notiﬁable	O
Diseases	O
Information	O
System	O
(	O
Sistema	O
de	O
Informação	O
de	O
Agravos	O
de	O
Notiﬁcação	O
,	O
SINAN	O
)	O
were	O
used	O
to	O
calculate	O
case	O
death	O
rates	O
for	O
IPD	B-Pneumococcal_Disease_Type
(	O
25	O
.	O
02	O
%	O
)	O
.	O
16	O

Pneumonia	B-Pneumococcal_Disease_Type
estimates	O
were	O
based	O
on	O
hospitalisations	O
due	O
to	O
all	O
-	O
causes	O
pneumonia	B-Pneumococcal_Disease_Type
identiﬁed	O
in	O
the	O
SIH	O
/	O
SUS	O
database	O
,	O
and	O
adjusted	O
to	O
include	O
hospitalisations	O
at	O
the	O
private	O
system	O
.	O

Since	O
Brazilian	O
data	O
for	O
the	O
number	O
of	O
pneumonia	B-Pneumococcal_Disease_Type
cases	O
treated	O
in	O
outpatient	O
healthcare	O
facilities	O
were	O
absent	O
,	O
estimates	O
were	O

based	O
on	O
the	O
number	O
of	O
hospitalisations	O
due	O
to	O
pneumonia	B-Pneumococcal_Disease_Type
and	O
the	O
proportion	O
of	O
children	O
<	O
5	O
seen	O
in	O
emergency	O
rooms	O
who	O
were	O
hospitalised	O
.	O

Data	O
from	O
the	O
Brazilian	O
literature	O
indicated	O
that	O
40e44	O
%	O
of	O
the	O
infants	O
and	O
18e28	O
%	O
of	O
children	O
aged	O
1e4	O
years	O
with	O
pneumonia	B-Pneumococcal_Disease_Type
diagnosed	O
at	O
the	O
public	O
emergency	O

rooms	O
are	O
hospitalised	O
.	O
17	O
18	O
A	O
household	O
survey	O
showed	O
a	O
higher	O
proportion	O
of	O
hospitalisation	O
at	O
the	O
private	O
healthcare	O
system	O
.	O
19	O
The	O
all	O
-	O
causes	O
pneumonia	B-Pneumococcal_Disease_Type
incidence	O
rate	O
in	O
under	O
-	O
5	O
children	O
(	O
93	O
.	O
4	O
/	O
1000	O
)	O
was	O
estimated	O
from	O
the	O
numbers	O
of	O
cases	O
treated	O
in	O
hospital	O
and	O
ambulatory	O
settings	O
in	O
both	O
public	O
and	O
private	O
systems	O
,	O
divided	O
by	O
the	O
<	O
5	O
population	O
.	O

Data	O
on	O
radiologically	O
conﬁrmed	O
all	O
-	O
causes	O
pneumonia	O
were	O

used	O
to	O
estimate	O
the	O
proportion	O
of	O
pneumococcal	O
pneumonia	B-Pneumococcal_Disease_Type
among	O
all	O
-	O
causes	O
pneumonia	B-Pneumococcal_Disease_Type
.	O

Data	O
from	O
Brazilian	O
literature	O
showed	O
that	O
96e100	O
%	O
of	O
children	O
<	O
5	O
with	O
suspected	O
pneu	O
-	O
monia	O
seen	O
in	O
emergency	O
rooms	O
have	O
a	O
chest	O
x	O
-	O
ray	O
,	O
and	O
74e98	O
%	O
of	O
them	O
have	O
radiologically	O
conﬁrmed	O
pneumonia	B-Pneumococcal_Disease_Type
.	O
17	O
20	O
A	O
study	O

indicated	O
S	O
pneumoniae	O
to	O
be	O
responsible	O
for	O
21	O
%	O
of	O
radiologically	O
conﬁrmed	O
pneumonia	O
in	O
children	O
<	O
5	O
.	O
21	O
Based	O
on	O
these	O
data	O
,	O
the	O
proportion	O
of	O
all	O
-	O
causes	O
pneumonia	B-Pneumococcal_Disease_Type
due	O
to	O
pneumococcus	O
in	O
hospital	O
and	O
outpatient	O
settings	O
was	O
estimated	O
.	O

Case	O
death	O
rate	O
(	O
0	O
.	O
8	O
%	O
)	O
was	O
based	O
on	O
data	O
from	O
the	O
National	O
Mortality	O
Infor	O
-	O

Status	O
quo	O

PCV10	O

Introduced	O

Invasive	O
Pneumococcal	O
Disease	O

Pneumococcal	O
pneumonia	O

Pneumococcal	O
Acute	O
Otitis	O
Media	O

Vaccinated	O

Not	O
Vaccinated	O

Vaccine	O

serotype	O

Non	O
-	O
vaccine	O
serotype	O

Go	O
to	O
node	O
Go	O
to	O
node	O

Go	O
to	O
node	O

Go	O
to	O
node	O

Disability	O

No	O
sequelae	O

mation	O
System	O
(	O
Sistema	O
de	O
Informação	O
sobre	O
Mortalidade	O
,	O
SIM	O
)	O
.	O
22	O
Similar	O
rates	O
were	O
found	O
in	O
the	O
literature	O
.	O
17	O
20	O
It	O
was	O
assumed	O
that	O
no	O
death	O
occurred	O
in	O
children	O
with	O
pneumonia	O
treated	O
at	O
outpatient	O
healthcare	O
facilities	O
.	O

Data	O
from	O
SIREVA	O
II	O
(	O
Network	O
Surveillance	O
System	O
for	O
the	O
Bacterial	O
Agents	O
Responsible	O
for	O
Pneumonia	O
and	O
Meningitis	O
)	O
on	O
the	O
distribution	O
of	O
pneumococcal	O
serotypes	O
in	O
Brazil	O
,	O
by	O
age	O
group	O
and	O
clinical	O
diagnosis	O
,	O
were	O
used	O
to	O
estimate	O
the	O
potential	O
coverage	O
of	O
the	O
PCV10	O
against	O
IPD	O
and	O
pneumonia23	O

As	O
no	O
valid	O
data	O
exist	O
for	O
the	O
frequency	O
of	O
AOM	O
in	O
children	O

<	O
5	O
in	O
Brazil	O
,	O
data	O
from	O
a	O
population	O
-	O
based	O
Mexican	O
study	O
,	O
with	O
living	O
conditions	O
similar	O
to	O
the	O
Brazilian	O
population	O
,	O
were	O
used	O

(	O
table	O
1	O
)	O
.	O
24	O
This	O
study	O
reported	O
a	O
cumulative	O
incidence	O
of	O
AOM	O
of	O
2	O
.	O
34	O
episodes	O
per	O
child	O
by	O
age	O
5	O
,	O
with	O
53	O
.	O
84	O
%	O
of	O
cases	O
occurring	O
in	O
the	O
ﬁrst	O
year	O
of	O
life	O
.	O

The	O
hospitalisation	O
rate	O
due	O
to	O
complicated	O
AOM	O
was	O
based	O
on	O
data	O
from	O
the	O
SIH	O
/	O
SUS	O
data	O
-	O

Figure	O
1	O
Simplified	O
decision	O
-	O
tree	O
.	O

base	O
and	O
adjusted	O
to	O
include	O
events	O
treated	O
at	O
the	O
private	O

J	O
Epidemiol	O
Community	O
Health	O
2012	O
;	O
66	O
:	O
210e217	O
.	O

doi	O
:	O
10	O
.	O
1136	O
/	O
jech	O
.	O
2010	O
.	O
111880	O
211	O

Child	O
and	O
infant	O
health	O

Table	O
1	O
Epidemiological	O
,	O
vaccine	O
and	O
healthcare	O
costs	O
parameters	O
used	O
in	O
the	O
cost	O
-	O
effectiveness	O
analysis	O
of	O
the	O
10	O
-	O
valent	O
pneumococcal	O
conjugate	O
vaccine	O
(	O
PCV10	O
)	O
in	O
Brazil	O

Base	O
case	O

Table	O
1	O
Continued	O

Parameter	O

AOM	O

Base	O
case	O

estimate	O
Source	O

Parameter	O

IPD	O
*	O

Annual	O
incidence	O
of	O
IPD	O
in	O
(	O
/	O
100000	O
)	O

Age	O
distribution	O
(	O
%	O
)	O

<	O
12	O
months	O

estimate	O
Source	O

Cumulative	O
incidence	O
of	O
AOM	O
without	O
complication	O
in	O
children	O

Sequelae	O
(	O
%	O
)	O

Deafness	O
8	O
.	O
49	O
12e15	O

Neurological	O
sequelae	O
11	O
.	O
32	O

Vaccine	O
efficacy	O
against	O
IPD	O
due	O
to	O
vaccine	O
serotypes	O
(	O
%	O
)	O
y	O

<	O
23	O
months	O
94	O
.	O
0	O
28	O

24e60	O
months	O
94	O
.	O
0	O

Costsz	O

Hospital	O
treatmentx	O

Public	O
healthcare	O
system	O
(	O
77	O
%	O
)	O
1135	O
.	O
11	O
10	O

Private	O
healthcare	O
system	O
(	O
23	O
%	O
)	O
1714	O
.	O
82	O
34	O

Family	O
costs	O
{	O
57	O
.	O
49	O

Indirect	O
costs	O
*	O
*	O
202	O
.	O
93	O

Pneumonia	O

Vaccine	O
efficacy	O
against	O
AOM	O
due	O
to	O
vaccine	O
serotypes	O
(	O
%	O
)	O
y	O

<	O
23	O
months	O
57	O
31	O
32	O

24e60	O
months	O
0	O

Costs	O
of	O
AOM	O
without	O
complication	O
Ambulatory	O
treatmentyy	O

Public	O
healthcare	O
system	O
(	O
73	O
%	O
)	O
17	O
.	O
65	O
35	O

Private	O
healthcare	O
system	O
(	O
27	O
%	O
)	O
77	O
.	O
45	O
34	O

Family	O
costs	O
{	O
14	O
.	O
50	O

Indirect	O
costs	O
*	O
*	O
15	O
.	O
65	O

Costs	O
of	O
complicated	O
AOM	O
Hospital	O
treatmentx	O

Annual	O
all	O
-	O
causes	O
pneumonia	O
incidence	O
in	O
children	O

<	O
5	O
years	O
(	O
/	O
1000	O
)	O

Distribution	O
of	O
treatment	O
type	O
(	O
%	O
)	O

93	O
.	O
4	O
10	O

Family	O
costs	O
{	O
27	O
.	O
30	O

Indirect	O
costs	O
*	O
*	O
62	O
.	O
60	O

Disability	O
-	O
adjusted	O
life	O
years	O
parameters	O

Percentage	O
of	O
pneumonia	O
pneumococcal	O
due	O
to	O
PCV10	O
-	O
serotypes	O

78	O
.	O
9	O
23	O

Vaccine	O

Vaccination	O
coverage	O
rates	O
(	O
%	O
)	O

1st	O
year	O
of	O
the	O
universal	O
vaccination	O
programme	O
80	O
[	O
Authors’	O

2nd	O
year	O
90	O

3rde25th	O
year	O
95	O

assumption	O
]	O

Costsz	O

Hospital	O
treatmentx	O

Ambulatory	O
treatmentyy	O

Public	O
healthcare	O
system	O
(	O
73	O
%	O
)	O
25	O
.	O
60	O
35	O

Private	O
healthcare	O
system	O
(	O
27	O
%	O
)	O
108	O
.	O
13	O
34	O

Family	O
costs	O
{	O

Hospital	O
treatment	O
43	O
.	O
32	O

Ambulatory	O
treatment	O
16	O
.	O
45	O

Indirect	O
costs	O
*	O
*	O

Hospital	O
treatment	O
162	O
.	O
76	O

Ambulatory	O
treatment	O
78	O
.	O
25	O

Continued	O

*	O
Invasive	O
pneumococcal	O
disease	O
(	O
IPD	O
)	O
includes	O
pneumococcal	O
meningitis	O
and	O
pneumococcal	O
sepsis	O
.	O

It	O
was	O
assumed	O
that	O
the	O
PCV10	O
would	O
have	O
the	O
same	O
efficacy	O
of	O
PCV7	O
.	O

Costs	O
in	O
2004	O
reals	O
(	O
R$	O
)	O
.	O

Hospital	O
treatment	O
costs	O
include	O
the	O
value	O
of	O
ambulatory	O
treatment	O
,	O
hospitalisation	O
,	O
and	O
two	O
medical	O
visits	O
(	O
pre	O
-	O
and	O
posthospitalisation	O
)	O
.	O

Family	O
costs	O
include	O
transport	O
and	O
the	O
medication	O
costs	O
paid	O
by	O
families	O
.	O

*	O
*	O
Indirect	O
costs	O
include	O
care	O
giver	O
productivity	O
losses	O
.	O

Ambulatory	O
treatment	O
costs	O
include	O
the	O
value	O
of	O
medical	O
visits	O
,	O
diagnostic	O
testing	O
(	O
chest	O
radiograph	O
in	O
pneumonia	O
cases	O
)	O
and	O
medication	O
.	O

AOM	O
,	O
acute	O
otitis	O
media	O
.	O

healthcare	O
system	O
.	O

Data	O
from	O
a	O
Brazilian	O
study	O
on	O
the	O
micro	O
-	O
biology	O
of	O
AOM	O
in	O
children	O
were	O
used	O
to	O
estimate	O
the	O
propor	O
-	O
tion	O
of	O
AOM	O
caused	O
by	O
S	O
pneumoniae	O
and	O
the	O
proportion	O
of	O
pneumococcal	O
AOM	O
caused	O
by	O
PCV10	O
-	O
serotypes	O
.	O
25	O

212	O
J	O
Epidemiol	O
Community	O
Health	O
2012	O
;	O
66	O
:	O
210e217	O
.	O

doi	O
:	O
10	O
.	O
1136	O
/	O
jech	O
.	O
2010	O
.	O
111880	O

Standard	O
methods	O
were	O
used	O
for	O
estimating	O
DALYs	O
,	O
including	O
age	O
weighting	O
,	O
discounting	O
and	O
disability	O
weights	O
.	O
26	O
Parameters	O
and	O
assumptions	O
for	O
DALYs	O
estimates	O
are	O
presented	O
in	O
table	O
1	O
.	O

Vaccine	O
efficacy	O
and	O
vaccination	O
programme	O

Vaccines	O
were	O
assumed	O
to	O
be	O
administered	O
in	O
four	O
doses	O
at	O
age	O
2	O
,	O
4	O
,	O
6	O
and	O
12e15	O
months	O
,	O
as	O
in	O
the	O
PCV10	O
clinical	O
trials	O
.	O
27	O
Since	O
PCV10’s	O
licensure	O
was	O
based	O
on	O
immunogenicity	O
data	O
,	O
it	O
was	O
assumed	O
that	O
the	O
PCV10	O
four	O
-	O
dose	O
schedule	O
efﬁcacy	O
against	O
vaccine	O
-	O
speciﬁc	O
serotypes	O
would	O
be	O
the	O
same	O
as	O
the	O
PCV7	O
four	O
-	O
dose	O
schedule	O
(	O
table	O
1	O
)	O
.	O
28e32	O
It	O
was	O
assumed	O
that	O
the	O
PCV10	O
would	O
confer	O
protection	O
against	O
pneumonia	O
and	O
AOM	B-Pneumococcal_Disease_Type
only	O
for	O
the	O
ﬁrst	O
2	O
years	O
of	O
life	O
,	O
whereas	O
vaccine’s	O
protection	O
against	O
IPD	B-Pneumococcal_Disease_Type
would	O
be	O

kept	O
unchanged	O
until	O
5	O
years	O
of	O
age	O
.	O
29	O
31	O
32	O

The	O
PCV10	O
was	O
assumed	O
to	O
be	O
coadministered	O
with	O
routine	O
childhood	O
vaccines	O
(	O
DTPw	O
/	O
Hib	O
,	O
hepatitis	O
B	O
and	O
OPV	O
)	O
.	O

This	O
approach	O
avoids	O
additional	O
visits	O
,	O
reduces	O
administration	O
costs	O
and	O
enhances	O
compliance	O
and	O
vaccination	O
coverage	O
.	O

It	O
was	O
assumed	O
that	O
all	O
children	O
initiating	O
vaccination	O
would	O
complete	O
the	O
four	O
-	O
dose	O
schedule	O
.	O

The	O
vaccination	O
coverage	O
rate	O
was	O
assumed	O
to	O
be	O
80	O
%	O
and	O
90	O
%	O
,	O
in	O
the	O
ﬁrst	O
and	O
second	O
year	O
of	O
the	O
universal	O
vaccination	O
programme	O
,	O
and	O
95	O
%	O
from	O
the	O
third	O
to	O
the	O
25th	O
year	O
.	O

Possible	O
adverse	O
events	O
associated	O
with	O
vaccination	O
were	O
not	O
taken	O
into	O
account	O
in	O
this	O
analysis	O
.	O

With	O
the	O
current	O
strategy	O
of	O
pneumococcal	O
vaccination	O
of	O
high	O
-	O
risk	O
children	O
,	O
36	O
570	O
doses	O
of	O
PCV7	O
were	O
administered	O
to	O
children	O
<	O
5	O
in	O
2004	O
.	O
33	O
This	O
number	O
was	O
used	O
to	O
estimate	O
the	O
annual	O
costs	O
of	O
the	O
current	O
vaccination	O
strategy	O
.	O

Costs	O
estimates	O

Table	O
1	O
summarises	O
the	O
healthcare	O
costs	O
parameters	O
.	O

A	O
‘top	O
-	O
down’	O
costing	O
approach	O
was	O
used	O
.	O

Costs	O
were	O
based	O
on	O
aggre	O
-	O
gate	O
information	O
,	O
representing	O
national	O
average	O
values	O
paid	O
by	O
the	O
Ministry	O
of	O
Health	O
and	O
healthcare	O
organisations	O
,	O
considered	O
appropriate	O
for	O
this	O
study’s	O
objectives	O
.	O

Hospitalisation	O
costs	O
were	O
obtained	O
from	O
SIH	O
/	O
SUS	O
system	O
and	O
the	O
Tabela	O
Única	O
Nacional	O
de	O
Equivalência	O
de	O
Procedimentos	O
,	O
TUNEP	O
)	O
,	O
a	O
list	O
of	O
procedures	O
deﬁned	O
by	O
the	O
National	O
Health	O
Agency	O
(	O
Agência	O
Nacional	O
de	O
Saúde	O
,	O
ANS	O
)	O
that	O
determines	O
the	O
value	O
of	O

procedures	O
performed	O
in	O
the	O
Public	O
Healthcare	O
System	O
/	O
SUS	O
for	O
private	O
-	O
health	O
-	O
plan	O
users	O
,	O
proxy	O
costs	O
for	O
the	O
private	O
healthcare	O
system	O
.	O
34	O
Direct	O
costs	O
of	O
ambulatory	O
treatments	O
were	O
obtained	O
from	O
the	O
Ambulatory	O
Information	O
System	O
(	O
Sistema	O
de	O
Infor	O
-	O
mação	O
Ambulatorial	O
,	O
SIA	O
/	O
SUS	O
)	O
and	O
from	O
the	O
TUNEP	O
.	O
34	O
35	O
Ambulatory	O
treatment	O
costs	O
included	O
medical	O
visits	O
,	O
diagnostic	O
tests	O
and	O
medication	O
(	O
drug	O
resource	O
based	O
on	O
clinical	O
guidelines	O
)	O
.	O

Direct	O
family	O
costs	O
included	O
transportation	O
costs	O
and	O
medica	O
-	O
tion	O
paid	O
by	O
the	O
families	O
.	O

Transportation	O
cost	O
was	O
calculated	O
based	O
on	O
the	O
unit	O
cost	O
of	O
the	O
average	O
price	O
of	O
public	O
trans	O
-	O
portation	O
in	O
Brazil	B-Study_Location
(	O
R$1	O
.	O
60	O
)	O
and	O
the	O
number	O
of	O
visits	O
needed	O
during	O
treatment	O
.	O

Indirect	O
costs	O
were	O
estimated	O
based	O
on	O
time	O
lost	O
by	O
a	O
parent	O
of	O
a	O
child	O
with	O
PD	O
using	O
the	O
human	O
capital	O
approach	O
.	O

Production	O
losses	O
were	O
based	O
on	O
maternal	O
absence	O
from	O
work	O
to	O
take	O
care	O
of	O
a	O
sick	O
child	O
.	O

Maternal	O
absence	O
from	O
work	O
was	O
valued	O
based	O
on	O
the	O
average	O
daily	O
income	O
of	O
economically	O
active	O
Brazilian	O
women	O
.	O

Each	O
day	O
lost	O
was	O
valued	O
at	O
R$15	O
.	O
65	O
.	O

For	O
each	O
clinical	O
syndrome	O
,	O
the	O
productivity	O
costs	O
were	O
calculated	O
based	O
on	O
the	O
average	O
length	O
of	O
stay	O
in	O
hospital	O
retrieved	O
from	O
SIH	O
/	O
SUS	O
(	O
10	O
days	O
for	O
IPD	B-Pneumococcal_Disease_Type
and	O
5	O
days	O
for	O
pneumonia	B-Pneumococcal_Disease_Type
)	O
,	O
or	O
the	O
clinical	O
course	O
of	O
disease	O
treated	O
in	O
an	O
ambulatory	O
setting	O
(	O
5	O
days	O
for	O
pneumonia	B-Pneumococcal_Disease_Type
and	O
1	O
day	O
for	O
AOM	B-Pneumococcal_Disease_Type
)	O
.	O

The	O
model	O
did	O
not	O
take	O
into	O
account	O
future	O
productivity	O
losses	O
due	O
to	O
child	O
premature	O
death	O
.	O

As	O
the	O
PCV10	O
price	O
was	O
still	O
unavailable	O
at	O
the	O
time	O
the	O
analysis	O
was	O
conducted	O
,	O
a	O
price	O
of	O
US$15	O
(	O
R$39	O
.	O
75	O
)	O
per	O
vaccine	O
dose	O
was	O
assumed	O
in	O
the	O
base	O
case	O
.	O

The	O
assumed	O
price	O
was	O
very	O
close	O
to	O
the	O
price	O
(	O
R$31	O
.	O
00	O
)	O
negotiated	O
by	O
the	O
Ministry	O
of	O
Health	O
in	O
2009	O
.	O

Following	O
the	O
methodology	O
used	O
in	O
a	O
previous	O
study	O
,	O
the	O
administration	O
costs	O
per	O
dose	O
were	O
calculated	O
as	O
US$1	O
(	O
R$2	O
.	O
65	O
)	O
.	O

36	O
Vaccine	O
wastage	O
rate	O
was	O
set	O
at	O
5	O
%	O
,	O
considering	O
a	O
single	O
-	O
dose	O
package	O
,	O
and	O
the	O
total	O
cost	O
of	O
each	O
dose	O
was	O

R$44	O
.	O
39	O
.	O

